<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55406">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02000232</url>
  </required_header>
  <id_info>
    <org_study_id>1U01FD004257-01</org_study_id>
    <nct_id>NCT02000232</nct_id>
  </id_info>
  <brief_title>Impact of Unapproved Drug Initiative on Colchicine Use</brief_title>
  <official_title>Impact of Unapproved Drug Initiative on Colchicine Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measure if FDA regulation of Colchicne in 2009 has resulted in safer use in clinical
      settings.

      Our study will assess the impact of this Initiative on colchicine use and will provide data
      that supports its continuation and expansion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Frequency of use of colchicine in an unapproved fashion in contemporary medical proactice.</measure>
    <time_frame>This is an oberservational study and patients will be followed for upto 2 years from enrollment.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We expect to understand the impact of regulatory approach to colchicine preparation and how marketing can affect clinical use patterns in the real world.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Diagnosis with Gout and use of colchicine</arm_group_label>
    <description>Observational study age 18+</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All adults diagnosed with gout. Patient's from Stanford hospital and clinics and VA Palo
        Alto Heath care system are eligible
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of gout

          -  Current use of colchicine/colcrys to treat gout

          -  Ablility to provide Informed consent

        Exclusion Criteria:

        -Inability to provide Informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narinder Bolaria</last_name>
      <phone>650-736-7081</phone>
      <email>nbolaria@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Eswar Krishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Eswar Krishnan</investigator_full_name>
    <investigator_title>Assistant Professor, Medicine - Immunology &amp; Rheumatology</investigator_title>
  </responsible_party>
  <keyword>gout</keyword>
  <keyword>colchicine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
